IE832472L - Benzodioxoles - Google Patents

Benzodioxoles

Info

Publication number
IE832472L
IE832472L IE832472A IE247283A IE832472L IE 832472 L IE832472 L IE 832472L IE 832472 A IE832472 A IE 832472A IE 247283 A IE247283 A IE 247283A IE 832472 L IE832472 L IE 832472L
Authority
IE
Ireland
Prior art keywords
radical
compound
general formula
alk
given above
Prior art date
Application number
IE832472A
Other versions
IE56092B1 (en
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of IE832472L publication Critical patent/IE832472L/en
Publication of IE56092B1 publication Critical patent/IE56092B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

1. Claims (for the Contracting States : BE, CH, LI, DE, FR, GB, IT, LU, NL, SE) Compounds of the general formula I see diagramm : EP0107622,P32,F1 in which R1 represents an alkyl, alkenyl or alkynyl radical that is unsubstituted or substituted by halogen having an atomic number of up to 35, lower alkoxy or by lower alkylthio and has, in total, that is to say including the substituents, a maximum of 12 carbon atoms, or represents a phenyl or naphthyl radical that is unsubstituted or substituted by lower alkyl, lower cycloalkyl, lower alkoxy, lower alkylthio, lower alkylsulphonyl, trifluoromethyl, hydroxy, lower alkanoyl, lower alkanoylamino, lower alkoxycarbonylamino and/or by lower alkylsulphonylamino, a monocyclic five-membered hetero ring of aromatic character having two nitrogen atoms or one nitrogen atom and/or one oxygen or sulphur atom in the ring or a six-membered hetero ring of aromatic character having one or two nitrogen atoms in the ring, or a bicyclic radical consisting of the said five- or six-membered hetero rings of aromatic character with a fused benzene ring, alk represents an alkylene, alkenylene or alkylidene radical having a maximum of 5 carbon atoms, n1 represents 0, 1 or 2 and n2 represents 0 or 1, R2 , R3 and R4 each represents, independently of the others, hydrogen, lower alkyl, lower alkoxy or halogen, and A represents the radical -O-R5 wherein R5 represents hydrogen or an alkyl radical having a maximum of 12 carbon atoms that is unsubstituted or is substituted by lower alkoxy or by halogen, 2- or 3-lower alkenyl, 2-lower alkynyl, phenyl-lower alkyl or cinnamyl, in which the phenyl radical may be substituted in the same manner as under R1 , or A represents the radical see diagramm : EP0107622,P33,F1 in which either R6 and R7 each represents, independently of the other, hydrogen or lower alkyl, or R6 and R7 are bonded to one another and, together with the adjacent nitrogen atom, represent optionally lower alkyl-substituted tetra- to hexa-methyleneimino, 4-morpholinyl or 1H-tetrazol-1-yl, salts of compounds of the general formula I in which A represents OR5 wherein R5 represents hydrogen, with bases, and acid addition salts of compounds of the general formula I in which the radical R1 has a basic character, radicals designated "lower" having a maximum of 7 carbon atoms. 1. Claims (for the Contracting State AT) A process for the manufacture of compounds of the formula I see diagramm : EP0107622,P36,F2 in which R1 represents an alkyl, alkenyl or alkynyl radical that is unsubstituted or substituted by halogen having an atomic number of up to 35, lower alkoxy or by lower alkylthio and has, in total, that is to say including the substituents, a maximum of 12 carbon atoms, or represents a phenyl or naphthyl radical that is unsubstituted or substituted by lower alkyl, lower cycloalkyl, lower alkoxy, lower alkylthio, lower alkylsulphonyl, trifluoromethyl, hydroxy, lower alkanoyl, lower alkanoylamino, lower alkoxycarbonylamino and/or by lower alkylsulphonylamino, a monocyclic five-membered hetero ring of aromatic character having two nitrogen atoms or one nitrogen atom and/or one oxygen or sulphur atom in the ring or a six-membered hetero ring of aromatic character having one or two nitrogen atoms in the ring, or a bicyclic radical consisting of the said five- or six-membered hetero rings of aromatic character with a fused benzene ring, alk represents an alkylene, alkenylene or alkylidene radical having a maximum of 5 carbon atoms, n1 represents 0, 1 or 2 and n2 represents 0 or 1, R2 , R3 and R4 each represents, independently of the others, hydrogen, lower alkyl, lower alkoxy or halogen, and A represents the radical -O-R5 wherein R5 represents hydrogen or an alkyl radical having a maximum of 12 carbon atoms that is unsubstituted or is substituted by lower alkoxy or by halogen, 2- or 3-lower alkenyl, 2-lower alkynyl, phenyl-lower alkyl or cinnamyl, in which the phenyl radical may be substituted in the same manner as under R1 , or A represents the radical see diagramm : EP0107622,P36,F3 in which either R6 and R7 each represents, independently of the other, hydrogen or lower alkyl, or R6 and R7 are bonded to one another and, together with the adjacent nitrogen atom, represent optionally lower alkyl-substituted tetra- to hexa-methyleneimino, 4-morpholinyl or 1H-tetrazol-1-yl, salts of compounds of the general formula I in which A represents OR5 wherein R5 represents hydrogen with bases, and acid addition salts of compounds of the general formula I in which the radical R1 has a basic character, radicals designated "lower" having a maximum of 7 carbon atoms, characterised in that a) a compound of the general formula II see diagramm : EP0107622,P37,F1 in which R1 , alk, n1 , n2 , R2 , R3 and R4 have the meanings given above, or a salt thereof, is reacted with a compound of the general formula III see diagramm : EP0107622,P37,F2 in which Hal represents halogen and A has the meaning given above, or with a salt of such a compound in which A represents OR5 wherein R5 represents hydrogen, or b) in a compound of the general formula IV see diagramm : EP0107622,P37,F3 in which A**b represents carboxy, lower alkoxycarbonyl or acetyl, and R1 , alk, n1 , n2 , R2 , R3 , R4 and A have the meanings given in claim 1, the radical A**b is replaced by hydrogen, or c) for the manufacture of a compound of the general formula I in which A has the meaning given above with the exception of a radical OR5 in which R5 represents hydrogen, and R1 , alk, n2 , R2 , R3 and R4 have the meanings given above and n1 represents 1 or 2, a compound of the general formula V see diagramm : EP0107622,P37,F4 is reacted with a compound of the general formula VI R1 -(alk)n2 -S(O)n1-c -OH or with an anhydride thereof, in which A1 has the meaning given above for A with the exception of a radical OR5 in which R5 represents hydrogen, n1-c represents 1 or 2 and R2 , R3 and R4 , and R1 , alk and n2 have the meanings given above, or d) for the manufacture of a compound in which n2 is 1 or R1 is an aliphatic radical according to the definition and R1 or n2 , as the case may be, alk, n2 , R2 , R3 , R4 and A have the meanings given above, a compound of the general formula VII R1 -(alk)n2-d -Z**d in which Z**d represents a reactively esterified hydroxy group, especially halogen having an atomic number of at least 17, R1 has the meaning given above and n2 represents 1 or, if R2 is an aliphatic radical, may alternatively be 0, or a compound of the general formula VIII see diagramm : EP0107622,P37,F5 in which Z**dd (cation) represents a monovalent anion or the normal equivalent of a polyvalent anion and R1 and n1 have the meanings given above, is reacted with a salt of a compound of the general formula IX see diagramm : EP0107622,P38,F1 in which n1 , R2 , R3 , R4 and A have the meanings given in claim 1, or e) a metal compound, optionally formed in situ, of the general formula Xa or Xb R1 -(alk)n2 -M1 see diagramm : EP0107622,P38,F2 in which M1 represents a monovalent metal ion and M2 represents a divalent metal ion and R, alk and n2 have the meanings given above, is reacted with a compound of the general XIa or XIb see diagramm : EP0107622,P38,F3 see diagramm : EP0107622,P38,F4 in which Hal represents halogen and n1 , R2 , R3 , R4 and A have the meanings given above, or f) for the manufacture of a compound of the general formula I in which A represents OR5 wherein R5 represents hydrogen, and R1 , alk, n1 , n2 , R2 , R3 and R4 have the meanings given above, or a salt of this compound : in a compound of the general formula XIII see diagramm : EP0107622,P38,F5 in which A**f represents a group that can be converted into the carboxy group and R1 , alk, n1 , n2 , R2 , R3 and R4 have the meanings given above, the group A**f is converted into the carboxy group in free or salt form, or g) for the manufacture of a compound of the general formula I in which A has the meaning given above with the exception of a radical OR5 in which R5 represents hydrogen, and R1 , alk, n1 , n2 , R2 and R3 have the meanings given above : in a compound of the general formula XIV see diagramm : EP0107622,P38,F6 in which A**g represents a radical that can be converted into a radical CO-A1 in which A1 has the meaning given above for A with the exception of a radical OR5 in which R5 represents hydrogen, and R1 , alk, n1 , n2 , R2 , R3 and R4 have the meanings given in claim 1, the radical A**g is converted into the radical -CO-A1 , and h) if desired, a compound of the general formula I in which n1 represents 0 or 1 is oxidised to form the corresponding compound in which n1 represents 1 or 2, or i) if desired, a compound of the general formula I in which n1 represents 2 or 1 is reduced to form the corresponding compound in which n1 represents 1 or 0, and/or, if desired, a resulting compound of the general formula I is converted in a different manner known per se into a different compound of the general formula I, and/or a compound of the general formula I obtained in the form of a racemate is separated into the optical antipodes, and/or a resulting compound of the general formula I in which A represents OR5 wherein R5 represents hydrogen is converted into a salt with a base, or such a compound is freed from a resulting salt, or a resulting compound of the general formula I of basic character is converted into an acid addition salt, or such a compound is freed from a resulting salt.
IE2472/83A 1982-10-22 1983-10-21 Novel benzodioxole derivatives,processes for the manufacture thereof and corresponding pharmaceutical compositions IE56092B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH616382 1982-10-22

Publications (2)

Publication Number Publication Date
IE832472L true IE832472L (en) 1984-04-22
IE56092B1 IE56092B1 (en) 1991-04-10

Family

ID=4305256

Family Applications (1)

Application Number Title Priority Date Filing Date
IE2472/83A IE56092B1 (en) 1982-10-22 1983-10-21 Novel benzodioxole derivatives,processes for the manufacture thereof and corresponding pharmaceutical compositions

Country Status (16)

Country Link
EP (1) EP0107622B1 (en)
JP (1) JPS5995284A (en)
AT (1) ATE30722T1 (en)
AU (1) AU567894B2 (en)
CA (1) CA1223874A (en)
DE (1) DE3374408D1 (en)
DK (1) DK485583A (en)
ES (5) ES526609A0 (en)
FI (1) FI833819A (en)
GR (1) GR78709B (en)
IE (1) IE56092B1 (en)
IL (1) IL70005A0 (en)
NO (1) NO833857L (en)
NZ (1) NZ206035A (en)
PT (1) PT77539B (en)
ZA (1) ZA837811B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0158596A3 (en) * 1984-04-06 1986-08-13 Ciba-Geigy Ag Benzodioxole derivatives, process for their preparation and pharmaceutical compositions
US6169107B1 (en) 1993-04-28 2001-01-02 Sumitomo Pharmaceutical Co., Ltd. Indoloylguanidine derivatives
AU2005307006B2 (en) 2004-10-29 2012-05-03 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as modulators of PPAR
ES2691548T3 (en) * 2005-10-25 2018-11-27 Kalypsys, Inc. Salts of PPAR modulators and methods to treat metabolic disorders
CN101007798B (en) * 2006-01-24 2011-01-26 中国人民解放军军事医学科学院毒物药物研究所 Benzodioxole derivatives and their preparation method and medicinal uses
CN101007804B (en) * 2006-01-25 2011-05-11 中国人民解放军军事医学科学院毒物药物研究所 1,3-benzodioxole-2,2-dicarboxylic acid derivatives and their preparation method and medicinal uses
US20080176861A1 (en) 2007-01-23 2008-07-24 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis
US8987188B2 (en) * 2010-10-04 2015-03-24 Firmenich Sa Benzodioxole derivatives as watery odorants

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3872105A (en) * 1973-06-11 1975-03-18 Merrell Inc Richard Derivatives of 1,3-benzodioxole-2-carboxylic acid
GR75464B (en) * 1981-04-24 1984-07-20 Ciba Geigy
EP0107623A1 (en) * 1982-10-22 1984-05-02 Ciba-Geigy Ag Benzodioxole derivatives, process for their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
ES8603860A1 (en) 1986-01-01
AU567894B2 (en) 1987-12-10
ZA837811B (en) 1984-08-29
ES543682A0 (en) 1986-06-16
ES543681A0 (en) 1986-01-01
GR78709B (en) 1984-09-27
FI833819A0 (en) 1983-10-19
DK485583D0 (en) 1983-10-21
FI833819A (en) 1984-04-23
NO833857L (en) 1984-04-24
ES8703449A1 (en) 1987-02-16
JPS5995284A (en) 1984-06-01
PT77539A (en) 1983-11-01
IE56092B1 (en) 1991-04-10
IL70005A0 (en) 1984-01-31
NZ206035A (en) 1987-03-06
ES8601959A1 (en) 1985-11-16
ES543683A0 (en) 1987-02-16
CA1223874A (en) 1987-07-07
DE3374408D1 (en) 1987-12-17
ES543684A0 (en) 1987-02-16
DK485583A (en) 1984-04-23
PT77539B (en) 1986-05-28
ATE30722T1 (en) 1987-11-15
ES526609A0 (en) 1985-11-16
AU2048983A (en) 1984-05-03
EP0107622B1 (en) 1987-11-11
EP0107622A1 (en) 1984-05-02
ES8703450A1 (en) 1987-02-16
ES8608506A1 (en) 1986-06-16

Similar Documents

Publication Publication Date Title
ATE15185T1 (en) BENZHYDRYLSULFINYLACETAMIDE DERIVATIVES AND THEIR USE IN THERAPEUTICS.
EP0205247A3 (en) Derivatives of quinuclidine
AU567894B2 (en) Benzodioxole derivatives
ATE38839T1 (en) PROCESS FOR THE PRODUCTION OF NUCLEOSIDALKYL, ARALKYL AND ARYLPHOSPHONITES AND PHOSPHONATES.
GB1384479A (en) Phosphorus-containing amidines
DE3572816D1 (en) PYRIDAZINONE INOTROPIC AGENTS
ES543556A0 (en) PROCEDURE FOR OBTAINING COMPOUNDS OF 6-HYDROXY- LOWER ALKYL-PENEM
ES540332A0 (en) PROCEDURE TO PREPARE NEW PIRIMIDO (2,1-B) BENZO- TIAZOLES
GB2107315B (en) Alpha epsilon alkane diisocyanates and their use in polyurethane production
ZA852359B (en) Enkephalinase inhibitors
DE69114352D1 (en) Improved chemiluminescent reagents and procedures.
ATE4951T1 (en) ISATOGEN DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND THEIR USE AS FUNGICIDES.
ATE6512T1 (en) AZOLYLALKYL-2,3-DIHYDROBENZOFURANE, FUNGICIDES CONTAINING THEM AND PROCESS FOR THEIR PRODUCTION.
RO85269B (en) Process for preparing 1, 2, 4-oxadiazine derivatives
ZA827040B (en) Triazinyallactams,a process for their preparation,their use as stabilizers for synthetic organic polymers and the polymers stabilized with them